Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice

Diabetes, Obesity and Metabolism

Volumn 13, Issue 4, 2011, Pages 337-347

  Zhang, X ^a   Wang, Z ^a   Huang, Y ^a   Wang, J ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Alogliptin; Antidiabetic drug; DPP IV inhibitor; Glycaemic control; Islets; Type 2 diabetes; Type 2 diabetes mellitus; cells

Indexed keywords

ALOGLIPTIN; GLUCOSE; HEMOGLOBIN A1C; POTASSIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IMMUNOHISTOCHEMISTRY; INS1 GENE; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID DIET; LOW DRUG DOSE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

EID: 79951867513     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01354.x     Document Type: Article

References (47)

1. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1962.
2. Bonora E. Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis 2008; 18: 74-83.
3. Wajchenberg BL. β-Cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
4. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
5. Bajaj M, Defronzo RA. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 2003; 10: 311-323.
6. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabet Med 2005; 22: 674-682.
7. Panunti B, Jawa AA, Fonseca VA. Mechanisms and therapeutic targets in type 2 diabetes mellitus. Drug Discov Today Dis Mech 2004; 2: 151-157.
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
9. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 2007; 23: 905-917.
10. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009; 124: 113-138.
11. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
12. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
13. Fan R, Li X, Gu X, Chan JC, Xu G. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab 2010; 12: 815-824.
14. Salehi M, Aulinger BA, D'Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 2008; 29: 367-379.
15. Combettes MM. GLP-1 and type 2 diabetes: physiology and new clinical advances. Curr Opin Pharmacol 2006; 6: 598-605.
16. Siddiqui NI. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Med J 2009; 18: 113-124.
17. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294.
18. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
19. Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009; 29: 55S-67S.
20. Feng J, Zhang Z, Wallace MB et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007; 50: 2297-2300.
21. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008; 589: 306-314.
22. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z. A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 1981; 30: 1045-1050.
23. Matsuo T, Odaka H, Ikeda H. Effects of an intestinal disaccharidase inhibitor (AO-128) on NIDDM and IDDM rat models. In: Goto Y, Kanazawa Y eds. Lessons from Animal Diabetes. The Tokyo Workshop 1990. London: Smith-Gordon; 171-175.
24. Takeuchi K, Moritoh Y, Asakawa T et al. Effects of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV alone or in combination with pioglitazone in obese and non-obese type 2 diabetes model rats and mice. Diabetes 2006; 55: A465.
25. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008; 588: 325-332.
26. Luo J, Quan J, Tsai J et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 1998; 47: 663-668.
27. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
28. Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
29. Mu J, Petrov A, Eiermann GJ et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009; 623: 148-54.
30. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35-39.
31. Korbutt GS, Elliott JF, Ao Z, Smith DK, Warnock GL, Rajotte RV. Large scale isolation, growth, and function of porcine neonatal islet cells. J Clin Invest 1996; 97: 2119-2129.
32. McCabe C, Samali A, O'brien T. β cell cytoprotective strategies: establishing the relative roles for iNOS and ROS. Biochem Biophys Res Commun 2006; 342: 1240-1248.
33. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
34. Yaney GC, Schultz V, Cunningham BA, Dunaway GA, Corkey BE, Tornheim K. Phosphofructokinase isozymes in pancreatic islets and clonal β-cells (INS-l). Diabetes 1995; 44: 1285-1289.
35. Yamashita T, Eto K, Okazaki Y et al. Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a β-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 2004; 145: 3566-3577.
36. McGinn S, Poronnik P, King M, Gallery ED, Pollock CA. High glucose and endothelial cell growth: novel effects independent of autocrine TGF-β1 and hyperosmolarity. Am J Physiol Cell Physiol 2003; 284: 1374-1386.
37. Naya FJ, Huang HP, Qiu Y et al. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/NeuroD-deficient mice. Genes Dev 1997; 11: 2323-2334.
38. Mobasheri A, Wray S, Marples D. Distribution of AQP2 and AQP3 water channels in human tissue microarrays. J Mol Histol 2005; 36: 1-14.
39. Dachicourt N, Serradas P, Giroix MH, Gangnerau MN, Portha B. Decreased glucose-induced cAMP and insulin release in islets of diabetic rats: reversal by IBMX, glucagon, GIP. Am J Physiol 1996; 271: E725-E732.
40. Roche E, Assimacopoulos-Jeannet F, Witters LA et al. Induction by glucose of genes coding for glycolytic enzymes in a pancreatic β-cell line (INS-1). J Biol Chem 1997; 272: 3091-3098.
41. Vidal-Puig AJ. Uncoupling expectations. Nat Genet 2000; 26: 387-388.
42. Brown ML, Schneyer AL. Emerging roles for the TGF β family in pancreatic β-cell homeostasis. Trends Endocrinol Metab 2010; 21: 441-448.
43. Itkin-Ansari P, Marcora E, Geron I et al. NeuroD1 in the endocrine pancreas: localization and dual function as an activator and repressor. Dev Dyn 2005; 233: 946-953.
44. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GS. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κB Activation in endothelial cells. J Biol Chem 2001; 276: 7614-7620.
45. Korn T, Anderson AC, Bettelli E, Oukka M. The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J Neuroimmunol 2007; 191: 51-60.
46. Leung PS, Carlsson PO. Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol 2001; 26: 155-164.
47. Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005; 31: 233-242.